Novartis AG (NYSE:NVS) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC trimmed its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 6.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 541,528 shares of the company's stock after selling 38,264 shares during the quarter. Corient Private Wealth LLC's holdings in Novartis were worth $52,696,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Gitterman Wealth Management LLC grew its holdings in shares of Novartis by 8.1% during the fourth quarter. Gitterman Wealth Management LLC now owns 3,324 shares of the company's stock valued at $323,000 after buying an additional 249 shares during the last quarter. Greenwich Wealth Management LLC raised its stake in shares of Novartis by 5.6% in the fourth quarter. Greenwich Wealth Management LLC now owns 12,378 shares of the company's stock worth $1,205,000 after purchasing an additional 653 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Novartis by 12.4% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 37,063 shares of the company's stock valued at $3,607,000 after buying an additional 4,091 shares during the last quarter. one8zero8 LLC acquired a new position in Novartis in the 4th quarter worth approximately $279,000. Finally, Choate Investment Advisors raised its position in Novartis by 11.9% during the 4th quarter. Choate Investment Advisors now owns 36,683 shares of the company's stock worth $3,570,000 after buying an additional 3,910 shares during the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Novartis Price Performance

NVS stock traded down $1.10 during mid-day trading on Friday, reaching $112.11. 3,595,355 shares of the company's stock were exchanged, compared to its average volume of 1,468,860. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92. The stock's 50 day moving average is $106.41 and its 200 day moving average is $107.55. The company has a market cap of $229.15 billion, a price-to-earnings ratio of 19.07, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53.

Novartis (NYSE:NVS - Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, research analysts expect that Novartis AG will post 8.45 EPS for the current year.

Novartis Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were given a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is 42.69%.

Wall Street Analyst Weigh In

Several analysts have recently commented on NVS shares. Barclays reaffirmed an "underweight" rating on shares of Novartis in a report on Monday, February 3rd. StockNews.com raised Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. Morgan Stanley began coverage on Novartis in a report on Wednesday, February 12th. They issued an "underweight" rating for the company. HSBC lowered Novartis from a "hold" rating to a "reduce" rating in a report on Wednesday, December 4th. Finally, Deutsche Bank Aktiengesellschaft raised Novartis from a "hold" rating to a "buy" rating in a report on Tuesday, February 4th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.